Gillin 1997.

Methods	Eight‐week randomised, double‐blind multicentre study
Participants	Outpatients fulfilling DSM‐III‐R criteria for non‐psychotic, moderate to severe major depressive disorder, with a score of at least 18 on the Hamilton Rating Scale for Depression‐17 item (HDRS‐17). Age range: 21‐55 years Exclusion criteria: patients engaged in shift work and with a primary sleep disorder independent of affective disturbance, current general medical condition, history of psychoactive substance use disorder within 12 months prior to study entry, current DSM‐III Axis I disorder (organic mental syndrome, bipolar disorder‐depressive, and schizophrenia, delusional disorder, psychotic disorder NOS), pregnancy, lactation, not use of contraception.
Interventions	Fluoxetine: 20 participants Nefazodone: 24 participants Fluoxetine dose range: 20‐60 mg/day Nefazodone dose range: 200‐500 mg/day
Outcomes	HDRS‐17, Inventory of Depressive Symptomatology (IDS)
Notes	Funding: by industry
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Randomised, no information about randomisation procedure
Allocation concealment (selection bias)	Unclear risk	No information provided
Blinding (performance bias and detection bias) All outcomes	Unclear risk	Double blind, no further information
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Quote: "double‐dummy dosing scheme", no other information
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Double blind, no further information
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Endpoint scores reported without denominators. Number and reasons for discontinuation reported
Selective reporting (reporting bias)	Unclear risk	Only the most frequently occurring adverse events (at least in 10% of patients) reported
Other bias	High risk	Quote: "this study was supported by Bristol‐Myers‐Squibb Pharmaceutical Research Institute", that produces nefazodone